These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27959289)

  • 21. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient.
    Jacobs DM; DiTursi S; Ruh C; Sharma R; Claus J; Banjade R; Rao GG
    Int J Antimicrob Agents; 2016 Aug; 48(2):225-7. PubMed ID: 27396948
    [No Abstract]   [Full Text] [Related]  

  • 23. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
    Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C
    J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit.
    Bennett KM; Scarborough JE; Sharpe M; Dodds-Ashley E; Kaye KS; Hayward TZ; Vaslef SN
    J Trauma; 2007 Aug; 63(2):307-11. PubMed ID: 17693828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO
    Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
    [No Abstract]   [Full Text] [Related]  

  • 30. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam.
    Barlow G; Morice A
    J Antimicrob Chemother; 2018 Aug; 73(8):2270-2271. PubMed ID: 29912407
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
    Wagenlehner FM; Alidjanov JF
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to Spellberg and Brass.
    Solomkin JS; Hershberger E; Eckmann C
    Clin Infect Dis; 2016 Feb; 62(4):526. PubMed ID: 26486708
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.
    Nicolau DP; Siew L; Armstrong J; Li J; Edeki T; Learoyd M; Das S
    J Antimicrob Chemother; 2015 Oct; 70(10):2862-9. PubMed ID: 26133566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis.
    Ozkiriş A; Evereklioglu C; Akgün H; Eşel D; Caner F; Erkiliç K
    Exp Eye Res; 2005 Mar; 80(3):361-7. PubMed ID: 15721618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
    Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
    Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
    Kuti JL; Ghazi IM; Quintiliani R; Shore E; Nicolau DP
    Int J Antimicrob Agents; 2016 Sep; 48(3):342-3. PubMed ID: 27451086
    [No Abstract]   [Full Text] [Related]  

  • 38. Noninferiority Doesn't Mean Not Inferior.
    Spellberg B; Brass EP
    Clin Infect Dis; 2016 Feb; 62(4):525-6. PubMed ID: 26486703
    [No Abstract]   [Full Text] [Related]  

  • 39. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
    Kaur R; Gautam V; Singhal L; Ray P
    J Antibiot (Tokyo); 2014 Aug; 67(8):603-4. PubMed ID: 24756027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.